We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Thomas W. Dubensky Jr., Ph.D. has served as the President & CEO of Tempest Therapeutics since joining the company in 2017. He brings significant expertise in the discovery, development and translation of novel immune therapies for the treatment of cancer. Prior to Tempest, Tom served as the Chief Scientific Officer of Aduro Biotech, where he led the development of first-in-class STING (stimulator of interferon genes) agonists. His leadership was instrumental in securing Aduro’s $750M collaboration with Novartis for the STING program. Before his role at Aduro, Tom served as Chief Scientific Officer of Immune Design, where he was responsible for leading the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. Prior to this, in 2007 he co-founded and served as Chief Scientific Officer of Anza Therapeutics, a biotechnology company that was spun out from Cerus Corporation. Tom has also served scientific leadership and strategic roles at Viagene, Chiron Corporation and Onyx Pharmaceuticals. Tom has co-authored more than 75 scientific papers and is an inventor on 44 issued U.S. patents with multiple pending applications. He received his B.A. in Bacteriology and Immunology from the University of California, Berkeley, and his Ph.D. at the University of Colorado Health Sciences Center. He conducted his post-doctoral fellowship at Harvard Medical School in the Department of Pathology.
This speaker's sessions: